Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Tirzepatide vs Placebo and Dulaglutide in T2D
NCT03131687Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 26 weeks. Started May 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03131687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131687.